Pacer Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Pacer Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-408	Closed	-$70K	–	1582
2021 Q1	$70K	Sell	408 -146	-26%	-$28.9K	﹤0.01%	1374
2020 Q4	$122K	Sell	554 -472	-46%	-$102K	﹤0.01%	1334
2020 Q3	$170K	Buy	+1,026	New	+$140K	﹤0.01%	1202
2018 Q4	–	Sell	-3,728	Closed	-$176K	–	1093
2018 Q3	$176K	Buy	+3,728	New	+$208K	0.01%	1044

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Pacer Advisors's MRTX Position: Q2 2021 in Review

Pacer Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 408 shares — an estimated $70K sold.

Pacer Advisors first reported a position in MRTX in Q3 2018 and held it in 4 quarters. The position peaked at $176K in Q3 2018. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

Pacer Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Pacer Advisors sold 408 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $70K.
Pacer Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and held it in 4 quarters.
Pacer Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $176K in Q3 2018.
245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.